Get the Stockscreener App
0.5801
11.69%
-0.0769
Decoy Therapeutics Inc stock is traded at $0.5801, with a volume of 350.11K.
It is down -11.69% in the last 24 hours and down -6.42% over the past month.
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
See More
Previous Close:
$0.657
Open:
$0.64
24h Volume:
350.11K
Relative Volume:
0.19
Market Cap:
$3.70M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.05%
1M Performance:
-6.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.5713
$0.6439
1-Week Range:
$0.5713
$0.7343
52-Week Range:
$0.5713
$1.41
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Name
Decoy Therapeutics Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
0.5801 | 4.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Stock (DCOY) Latest News
Decoy Therapeutics Announces Reverse Stock Split to Maintain Listing - TipRanks
Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com India
Biotech Decoy Therapeutics shrinks shares 12-to-1 to meet Nasdaq $1 rule - Stock Titan
SLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Decoy Therapeutics (DCOY) Stock Analysis Report | Financials & Insights - Benzinga España
Decoy Therapeutics shareholders approve reverse stock split and equity plan - Investing.com Nigeria
Decoy Therapeutics shareholders approve reverse stock split and equity plan By Investing.com - Investing.com India
Decoy Therapeutics Shareholders Approve Plan and Reverse Split - TipRanks
DCOY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DCOY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Decoy Therapeutics Joins Webull Corporate Connect Service Platfo - GuruFocus
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - marketscreener.com
Follow Decoy Therapeutics updates on Webull app now - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Finviz
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Gates Foundation backs Decoy's push for rapid, low-cost antivirals - Stock Titan
Decoy Therapeutics (DCOY) Stock Price, News & Analysis - MarketBeat
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Decoy Therapeutics (DCOY) Receives "Buy" Rating from Ladenburg T - GuruFocus
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
DCOY Stock Price, News & Analysis - Stock Titan
Decoy Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
DCOYDECOY THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access - TradingView
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
What is the current Price Target and Forecast for Decoy Therapeutics Inc (DCOY) - Zacks Investment Research
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
symbol__ Stock Quote Price and Forecast - CNN
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - The Globe and Mail
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy - GlobeNewswire
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Decoy Therapeutics Inc Stock (DCOY) Financials Data
There is no financial data for Decoy Therapeutics Inc (DCOY). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Decoy Therapeutics Inc Stock (DCOY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):